CMPX
Compass Therapeutics, Inc.NASDAQHealthcare$5.45+0.37%ClosedMarket Cap: $753.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.16
P/S
0.00
EV/EBITDA
-14.05
DCF Value
$0.12
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-43.6%
ROA
-30.3%
ROIC
-26.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $0.00 | $-15.7M | $-0.09 | — |
| FY 2025 | $0.00 | NaN% | $-72.8M | $-66.5M | $-0.42 | — |
| Q3 2025 | $0.00 | NaN% | $-15.8M | $-14.3M | $-0.10 | — |
| Q2 2025 | $0.00 | NaN% | $-21.1M | $-19.9M | $-0.14 | — |
| Q1 2025 | $0.00 | NaN% | $-18.0M | $-16.6M | $-0.12 | — |
| Q4 2024 | $0.00 | NaN% | $-16.6M | $-15.0M | $-0.11 | — |
| FY 2024 | $850.0K | 100.0% | $-56.6M | $-49.4M | $-0.36 | — |
| Q3 2024 | $0.00 | NaN% | $-12.2M | $-10.5M | $-0.08 | — |
| Q2 2024 | $850.0K | 100.0% | $-15.0M | $-13.1M | $-0.10 | — |
| Q1 2024 | $0.00 | NaN% | $-12.8M | $-10.8M | $-0.08 | — |
| Q4 2023 | $0.00 | NaN% | $-15.4M | $-13.4M | $-0.11 | — |
| FY 2023 | $0.00 | NaN% | $-50.4M | $-42.5M | $-0.33 | — |